ESR1 and cancer: This classification has assisted in stratifying hormonal receptor (HR)-positive cancers into Luminal A and Luminal B subgroups, with Luminal A cancers expressing both ER and PR, while Luminal B cancers are usually higher grades with expression of ER and with Ki67 positivity higher than 14% [14, 15].